Recently on January 12, 2015, the Company issued a report entitled "Low Natural Killer (NK) Activity Observed Across the Chronic Fatigue Syndrome (CFS) Disease Spectrum" that a biomarker natural killer cell cytotoxicity (NKCC), when low, was associated with more symptom severity and debilitation. This report has now been submitted as a scientific paper for peer-review and publication. The report includes a summary of 6 publications totaling over 150 CFS patients which indicates a relationship between increased severity of CFS and low NK cell activity. In 15 subjects with CFS studied by the Company, Ampligen(R) treatment of peripheral blood mononuclear cells in vitro increased the mean NK activity over 100%. Clinical testing is presently underway to determine whether or not NK augmentation by Ampligen(R), to the extent it may occur in vivo, is associated with decreased CFS disease severity and, specifically, increased physical performance.